ZP2495 Protects against Myocardial Ischemia/Reperfusion Injury in Diabetic Mice through Improvement of Cardiac Metabolism and Mitochondrial Function: The Possible Involvement of AMPK‐FoxO3a Signal Pathway

Authors:

Abstract
Coronary heart disease patients with type 2 diabetes were subject to higher vulnerability for cardiac ischemia‐reperfusion (I/R) injury. This study was designed to evaluate the impact of ZP2495 (a glucagon‐GLP‐1 dual‐agonist) on cardiac function and energy metabolism after myocardial I/R injury in db/db mice with a focus on mitochondrial function. C57BLKS/J‐lepr+/lepr+(BKS) and db/db mice received 4‐week treatment of glucagon, ZP131 (GLP‐1 receptor agonist), or ZP2495, followed by cardiac I/R injury. The results showed that cardiac function, cardiac glucose metabolism, cardiomyocyte apoptosis, cardiac mitochondrial morphology, and energetic transition were improved or ameliorated by ZP2495 to a greater extent than that of glucagon and ZP131.In vitrostudy showed that ZP2495, rather than glucagon, alleviated mitochondrial depolarization, cytochrome C release, and mitochondria ROS generation in neonatal rat ventricular myocytes subjected to high‐glucose and simulated I/R injury conditions, the effects of which were weaker in the ZP131 group. Furthermore, the expressions of Akt, FoxO3a, and AMPK phosphorylation were elevated by ZP2495 to a greater extent than that of ZP131. In conclusion, ZP2495 may contribute to the improvement of cardiac function and energy metabolism in db/db mice after myocardial I/R injury by improving mitochondrial function possibly through Akt/FoxO3a and AMPK/FoxO3a signal pathways.
Funding Information
  • Natural Science Foundation of Beijing Municipality (7152131)
  • National Natural Science Foundation of China (81570272, 81530058, 81300149, 81270168)
  • China National Funds for Distinguished Young Scientists (81325009)

This publication has 51 references indexed in Scilit: